Are you JAK2 positive and experiencing side effects with Ojjaara (momelotinib)?
Ojjaara was approved in 2023 specifically for adults with intermediate- or high-risk myelofibrosis who are experiencing anemia (low hemoglobin levels). It can be used for primary myelofibrosis, post-polycythemia vera, or post-essential Show Full Answer
Are you JAK2 positive and experiencing side effects with Ojjaara (momelotinib)?
Ojjaara was approved in 2023 specifically for adults with intermediate- or high-risk myelofibrosis who are experiencing anemia (low hemoglobin levels). It can be used for primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis.
This medication may be recommended if you've had anemia as a side effect from other JAK2 inhibitors like ruxolitinib or fedratinib.
Regarding JAK2 status, many people with myelofibrosis do have JAK2 mutations:
- Between 50-60% of people with myelofibrosis test positive for a JAK2 gene mutation
- JAK2 inhibitors like Ojjaara work by targeting the JAK2 protein pathway
While the search results don't detail specific side effects members are experiencing with Ojjaara, it would be helpful to discuss any symptoms you're noticing with your healthcare team. They can help determine if what you're experiencing is related to the medication and whether any adjustments might be needed.
Have you noticed any particular symptoms since starting Ojjaara? Sharing experiences with other myMPNteam members who are on this treatment might also provide helpful insights.
April 13
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
